The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised pha...

发表于 2026-9-23 14:07:48

DOI号:

文献链接:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71159-3/abstract

文献作者:Richard S Finn, MD[url=]a[/url] ∙ Prof John P Crown, MD[url=]b[/url] ∙ Istvan Lang, MD[url=]c[/url] ∙ Katalin Boer, MD[url=]d[/url] ∙ Prof Igor M Bondarenko, MD[url=]e[/url] ∙ Sergey O Kulyk, MD[url=]f[/url] ∙ Johannes Ettl, MD[url=]g[/url] ∙ Ravindranath Patel, MD[url=]h[/url] ∙ Tamas Pinter, MD[url=]i[/url] ∙ Marcus Schmidt, MD[url=]j[/url] ∙ Yaroslav Shparyk, MD[url=]k[/url] ∙ Anu R Thummala, MD[url=]l[/url] ∙ Nataliya L Voytko, MD[url=]m[/url] ∙ Camilla Fowst, MD[url=]n[/url] ∙ Xin Huang, PhD[url=]o[/url] ∙ Sindy T Kim, BS[url=]o[/url] ∙ Sophia Randolph, MD[url=]o[/url] ∙ Prof Dennis J Slamon, MD

备注信息:

发表于 2026-9-23 14:07:49

[其他期刊] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised pha...